ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been ...
SAINT LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their analytical validation study of ...
About Cofactor Genomics Cofactor Genomics is a commercial stage diagnostics company that bridges the precision medicine gap by decoding RNA to solve the biggest problems in healthcare. It accomplishes ...
Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their PREDAPT clinical trial (NCT04510129) results in head and neck ...
Cofactor Genomics announced the latest validation results for OncoPrism ®, Cofactor’s breakthrough RNA-based diagnostic approach at the RNA Society’s 30th Annual Meeting. The talk, presented by Dr.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Cofactor Genomics, a DNA sequencing service that once ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A St. Louis-based biotech ...
Jon Armstrong adds reagents to the sequencer machine at Cofactor Genomics in St. Louis. (2010 file photo by Sarah Conard) It’s rare for a company from the middle of the country to be chosen for Y ...
Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, today announced results from the PREDAPT non-small cell lung cancer (NSCLC) trial validating the company’s OncoPrism-NSCLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results